Get YouTube subscribers that watch and like your videos
Get Free YouTube Subscribers, Views and Likes

Exercise Training and Biomarkers

Follow
Michael Betel

How often does a study get you AMPED? Jonathan G. Stine, MD MSc, FACP leads by example and shares his latest study on the impact of different doses of aerobic exercise training for MASLD patients, with Michael Betel.

"The guidelines currently do recommend about 150 minutes per week of moderate intensity activities such as walking or light jogging or 75 minutes of vigorous intensity activity. However, nobody has really looked to see, are there additional benefits beyond the guidelinebased amounts".

1. Exercise Prescription for MASH Patients:
Dr. Stine emphasizes the importance of exercise for patients with Metabolic dysfunctionAssociated Steatohepatitis (MASH). The current guidelines recommend 150 minutes of moderateintensity or 75 minutes of vigorousintensity activity per week. The AMPED study aims to explore the benefits of exercise beyond these guidelines, focusing on the AMP kinase pathway, which plays a crucial role in energy balance and liver health.

2. Personalized Exercise Plans:
The AMP study is investigating whether personalized exercise prescriptions, tailored to individual capabilities and preferences, lead to better compliance and health outcomes. Dr. Stein highlights the importance of customizing exercise plans based on factors like frequency, intensity, time, and type of exercise to better fit patients' lifestyles and needs.

3. Clinical and Research Impact:
The AMPED study, funded by the NIH and conducted at Penn State University, is in its third year and aims to provide robust evidence supporting the benefits of exercise for MASH patients. Dr. Stine’s team uses tools like Fitbits for remote monitoring and selfreporting questionnaires to gather data. The goal is to establish that personalized exercise prescriptions can lead to improved compliance and measurable health benefits, ultimately advocating for exercise as a vital component of treatment for liver diseases.

Hepatol Commun. 2024 Jul; 8(7): e0464. Published online 2024 Jun 19.

posted by Dusevich70